Home › Acute Myeloid Leukemia › Illinois › Chicago
Acute Myeloid Leukemia clinical trials in Chicago, IL
27 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
- Northwestern, Chicago
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- US-Chigago IL-UHCHICAGO, Chicago
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- University of Chicago Comprehensive Cancer Center, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- and 1 more
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- University of Chicago Medicine, Chicago
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
RecruitingPhase 1
- University of Chicago Comprehensive Cancer Center, Chicago
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- and 2 more
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RecruitingPhase 1/2
- University of Chicago, Chicago
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
RecruitingPhase 1
- Lurie Children's Hospital-Chicago, Chicago
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
RecruitingPhase 1/2
- The University of Chicago Medical Center, Chicago
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RecruitingPhase 3
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
RecruitingPhase 3
- Lurie Children's Hospital-Chicago, Chicago
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
RecruitingPhase 1
- University of Chicago Comprehensive Cancer Center, Chicago
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- and 2 more
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
RecruitingPhase 2
- University of Illinois Cancer Center, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RecruitingPhase 1
- University of Chicago, Chicago
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
RecruitingPhase 1/2
- Northwestern University, Chicago
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecruitingPhase 1/2
- Northwestern, Chicago
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
RecruitingPhase 1
- Northwestern Medicine, Chicago
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RecruitingPhase 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RecruitingPhase 1
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX88 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Baldwin Park, CA41 studies
- Seattle, WA40 studies
- Durham, NC34 studies
- Columbus, OH34 studies
- Philadelphia, PA33 studies
- Atlanta, GA30 studies
- Tampa, FL30 studies
- Los Angeles, CA25 studies
- Portland, OR24 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.